<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643279</url>
  </required_header>
  <id_info>
    <org_study_id>COMPASS-HF</org_study_id>
    <nct_id>NCT00643279</nct_id>
  </id_info>
  <brief_title>Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)</brief_title>
  <official_title>Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      COMPASS-HF was a prospective, two-arm, randomized (1:1), multi-center, parallel controlled
      study. The purpose of the randomized study was to test the safety of an implantable
      hemodynamic monitor (IHM) and pressure sensor lead. The premise of this study was to compare
      the effectiveness of a novel heart failure management strategy based on information obtained
      from the IHM system in reducing heart failure morbidity compared to a strategy based on
      standard medical care alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COMPASS-HF was a prospective, two-arm, randomized (1:1), multi-center, parallel controlled
      study. The purpose of the randomized study was to test the safety of an implantable
      hemodynamic monitor (IHM) and pressure sensor lead. The premise of this study was to compare
      the effectiveness of a novel heart failure management strategy based on information obtained
      from the IHM system in reducing heart failure morbidity compared to a strategy based on
      standard medical care alone.

      After baseline evaluation and verification that entrance criteria were met, all subjects were
      implanted with a Chronicle IHM and pressure sensor lead. Following successful implantation,
      subjects were randomized to either the CHRONICLE group or CONTROL group. Subjects randomized
      to the CHRONICLE group were managed using Chronicle, specifically trended RV and estimated PA
      pressure, heart rate and activity data, whereas subjects randomized to the CONTROL group were
      treated conventionally without the use of the Chronicle data. In the case that implantation
      was not successful, subjects were exited from the study if no procedure related adverse
      events were identified; procedure related adverse events were followed through to resolution
      before the subject were withdrawn from the study.

      Subjects remained randomized until their six month clinic visit had been completed. Following
      the subject's six month visit, clinicians were granted access to the CONTROL subject's
      trended Chronicle data on the Chronicle website, and subjects were seen in the clinic for a
      protocol-required visit every six months until exit from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months.</measure>
    <time_frame>Within 6 months post-implant</time_frame>
    <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death, (3) results in the explant of any Chronicle IHM component, and/or (4) causes permanent loss of significant function of the implanted system.
Safety is defined as ≥ 80% of participants experiencing freedom from device related complications through 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as Measured by the Percentage of Participants Free From Implantable Hemodynamic Monitor Pressure Related Sensor Lead Failures Through 6 Months.</measure>
    <time_frame>Within 6 months post-implant</time_frame>
    <description>A pressure sensor failure was defined as a recognizable, abrupt, non-physiologic shift in pressure parameters.
Safety is defined as ≥ 90% of participants free from pressure sensor lead failure through 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Heart Failure-related Hospital Equivalents.</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Hospital equivalents (HE) were defined to include the following events:
Heart failure-related hospital admissions for 24 hours or longer
Heart failure-related emergency department visits and necessitates invasive treatment (e.g. IV diuretic administration).
Heart failure-related urgent visits and necessitates invasive treatment (e.g. IV diuretic administration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Characterize total health care utilization, the total number of all-cause hospitalization, emergency department, and urgent care visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Hospitalization Free</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>The number of days alive outside the hospital was calculated as the number of days of randomized follow-up minus the number of days hospitalized during the randomized follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Composite Response of Either &quot;Worsened&quot;, &quot;Improved&quot;, or &quot;Unchanged&quot;</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Worsened, Improved and Unchanged were defined as follows:
Worsened: Patient died, hospitalized for worsening heart failure, worsened NYHA Class Improved: Patient improved in NYHA Class Unchanged: Patient was neither improved nor worsened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Quality of life was measured by the Minnesota Living with Heart Failure (MLHF), a questionnaire with 21 questions and scored on a scale from 0 (good quality of life) to 105 (low quality of life).
Change in quality of life is defined as change from baseline to month 6. A participant must have completed a quality of life survey at the baseline visit and month 6 visit to be included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Class</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>New York Heart Association (NYHA) Classifications were defined as follows:
Class I - Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or angina.
Class II - Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.
Class III - Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.
Class IV - Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Walked During a Six Minute Hall Walk</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Patients completed six minute hall walk at baseline and 6 months. Outcome is change in hall walk distance from baseline to 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CHRONICLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chronicle Implantable Hemodynamic Monitor</intervention_name>
    <description>Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.</description>
    <arm_group_label>CHRONICLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with heart failure classified as New York Heart Association (NYHA) Class III
             and IV

          -  Subject has been managed with standard medical therapy for heart failure (such as
             diuretic, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor
             blockers (ARB), and beta-blocker for at least 3 months prior to the baseline
             evaluation

          -  Subject must have at least one heart failure-related hospitalization or emergency
             department visit requiring intravenous treatment within 6 months prior to baseline
             evaluation

        Exclusion Criteria:

          -  Subjects who are likely to be transplanted within 6 months from randomization or will
             remain hospitalized until transplantation

          -  Subjects with severe COPD or restrictive airway disease (recommended FEV1 less than or
             equal to 1 liter or 50% predicted)

          -  Subjects who are on continuous positive inotropic therapy

          -  Subjects with known atrial or ventricular septal defects

          -  Subjects with mechanical right heart valves

          -  Subjects with stenotic tricuspid or pulmonary valves

          -  Subjects with a presently implanted non-compatible pacemaker or ICD

          -  Subjects with cardiac resynchronization therapy which has not achieved optimal
             programming for more than 3 months

          -  Subjects with a major cardiovascular event within 3 months prior to baseline
             evaluation

          -  Subjects with a severe non-cardiac condition limiting 6 month survival

          -  Subjects with a primary diagnosis of pulmonary artery hypertension

          -  Subjects with serum creatinine greater than or equal to 3.5 mg/dL or on chronic renal
             dialysis

          -  Subjects enrolled in concurrent studies that may confound the results of this study

          -  Women who are pregnant or with child bearing potential and who are not on a reliable
             form of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bourge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Shands</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crawford LongHospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Heart Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Memorial Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul Heart</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian - Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular Associates</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital/Texas Heart</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <results_first_submitted>June 11, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>implantable hemodynamic monitor</keyword>
  <keyword>Intracardiac pressures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on March 13, 2003 and ended on November 16, 2004. All subjects were exited from the study on April 8, 2013. Twenty-nine US clinical centers participated in the COMPASS-HF study.</recruitment_details>
      <pre_assignment_details>Subjects were required to have a successful implant of the Chronicle® device prior to randomization. 277 subjects had an attempted implant, with 274 successfully implanted and randomized. 3 subjects had unsuccessful implant attempts and were exited prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="274"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="14"/>
                    <measurement group_id="B2" value="58" spread="13"/>
                    <measurement group_id="B3" value="58" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class III (NYHA III)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Class IV (NYHA IV)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months.</title>
        <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death, (3) results in the explant of any Chronicle IHM component, and/or (4) causes permanent loss of significant function of the implanted system.
Safety is defined as ≥ 80% of participants experiencing freedom from device related complications through 6 months.</description>
        <time_frame>Within 6 months post-implant</time_frame>
        <population>The analysis population for safety includes all subjects with an attempted implant of the Chronicle implantable hemodynamic monitoring device, including both successful implanted participants (274) and unsuccessful implanted participants (3). In total 277 participants were assessed for the safety objective.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects With Attempted Implant</title>
            <description>All subjects with an attempted implant of a Chronicle IHM.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months.</title>
          <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death, (3) results in the explant of any Chronicle IHM component, and/or (4) causes permanent loss of significant function of the implanted system.
Safety is defined as ≥ 80% of participants experiencing freedom from device related complications through 6 months.</description>
          <population>The analysis population for safety includes all subjects with an attempted implant of the Chronicle implantable hemodynamic monitoring device, including both successful implanted participants (274) and unsuccessful implanted participants (3). In total 277 participants were assessed for the safety objective.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Survival estimate at 6-months</non_inferiority_desc>
            <param_type>6-month survival rate</param_type>
            <param_value>91.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>88.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by the Percentage of Participants Free From Implantable Hemodynamic Monitor Pressure Related Sensor Lead Failures Through 6 Months.</title>
        <description>A pressure sensor failure was defined as a recognizable, abrupt, non-physiologic shift in pressure parameters.
Safety is defined as ≥ 90% of participants free from pressure sensor lead failure through 6 months.</description>
        <time_frame>Within 6 months post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects Successfully Implanted</title>
            <description>All subjects successfully implanted with a Chronicle IHM system</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by the Percentage of Participants Free From Implantable Hemodynamic Monitor Pressure Related Sensor Lead Failures Through 6 Months.</title>
          <description>A pressure sensor failure was defined as a recognizable, abrupt, non-physiologic shift in pressure parameters.
Safety is defined as ≥ 90% of participants free from pressure sensor lead failure through 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Survival estimate at 6-months</non_inferiority_desc>
            <param_type>6-month survival rate</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>98.9</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Heart Failure-related Hospital Equivalents.</title>
        <description>Hospital equivalents (HE) were defined to include the following events:
Heart failure-related hospital admissions for 24 hours or longer
Heart failure-related emergency department visits and necessitates invasive treatment (e.g. IV diuretic administration).
Heart failure-related urgent visits and necessitates invasive treatment (e.g. IV diuretic administration).</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Heart Failure-related Hospital Equivalents.</title>
          <description>Hospital equivalents (HE) were defined to include the following events:
Heart failure-related hospital admissions for 24 hours or longer
Heart failure-related emergency department visits and necessitates invasive treatment (e.g. IV diuretic administration).
Heart failure-related urgent visits and necessitates invasive treatment (e.g. IV diuretic administration).</description>
          <population>All randomized subjects</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.51" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.81" lower_limit="0.67" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Utilization</title>
        <description>Characterize total health care utilization, the total number of all-cause hospitalization, emergency department, and urgent care visits.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Utilization</title>
          <description>Characterize total health care utilization, the total number of all-cause hospitalization, emergency department, and urgent care visits.</description>
          <population>All randomized subjects</population>
          <units>Total number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Hospitalization Free</title>
        <description>The number of days alive outside the hospital was calculated as the number of days of randomized follow-up minus the number of days hospitalized during the randomized follow-up period.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Days Hospitalization Free</title>
          <description>The number of days alive outside the hospital was calculated as the number of days of randomized follow-up minus the number of days hospitalized during the randomized follow-up period.</description>
          <population>All randomized subjects</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.8" lower_limit="164.1" upper_limit="177.6"/>
                    <measurement group_id="O2" value="172.7" lower_limit="166.6" upper_limit="178.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Composite Response of Either &quot;Worsened&quot;, &quot;Improved&quot;, or &quot;Unchanged&quot;</title>
        <description>Worsened, Improved and Unchanged were defined as follows:
Worsened: Patient died, hospitalized for worsening heart failure, worsened NYHA Class Improved: Patient improved in NYHA Class Unchanged: Patient was neither improved nor worsened.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Composite Response of Either &quot;Worsened&quot;, &quot;Improved&quot;, or &quot;Unchanged&quot;</title>
          <description>Worsened, Improved and Unchanged were defined as follows:
Worsened: Patient died, hospitalized for worsening heart failure, worsened NYHA Class Improved: Patient improved in NYHA Class Unchanged: Patient was neither improved nor worsened.</description>
          <population>All randomized subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsend</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unchanged</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire</title>
        <description>Quality of life was measured by the Minnesota Living with Heart Failure (MLHF), a questionnaire with 21 questions and scored on a scale from 0 (good quality of life) to 105 (low quality of life).
Change in quality of life is defined as change from baseline to month 6. A participant must have completed a quality of life survey at the baseline visit and month 6 visit to be included in the analysis.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects completing a quality of life survey at the baseline visit and month 6 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire</title>
          <description>Quality of life was measured by the Minnesota Living with Heart Failure (MLHF), a questionnaire with 21 questions and scored on a scale from 0 (good quality of life) to 105 (low quality of life).
Change in quality of life is defined as change from baseline to month 6. A participant must have completed a quality of life survey at the baseline visit and month 6 visit to be included in the analysis.</description>
          <population>All randomized subjects completing a quality of life survey at the baseline visit and month 6 visit</population>
          <units>Index score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-69" upper_limit="42"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-73" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Class</title>
        <description>New York Heart Association (NYHA) Classifications were defined as follows:
Class I - Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or angina.
Class II - Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.
Class III - Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.
Class IV - Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized subjects with NYHA assessment completed at baseline and at 6 months were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>New York Heart Association (NYHA) Classifications were defined as follows:
Class I - Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or angina.
Class II - Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.
Class III - Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.
Class IV - Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>All randomized subjects with NYHA assessment completed at baseline and at 6 months were included in the analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distance Walked During a Six Minute Hall Walk</title>
        <description>Patients completed six minute hall walk at baseline and 6 months. Outcome is change in hall walk distance from baseline to 6 months.</description>
        <time_frame>6 Months post-implant</time_frame>
        <population>All randomized patients completing a hall walk at baseline and 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Walked During a Six Minute Hall Walk</title>
          <description>Patients completed six minute hall walk at baseline and 6 months. Outcome is change in hall walk distance from baseline to 6 months.</description>
          <population>All randomized patients completing a hall walk at baseline and 6 months.</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="98.8"/>
                    <measurement group_id="O2" value="-8.2" spread="114.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lab value abnormalities</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Decompensation of heart failure</sub_title>
                <counts group_id="E1" events="57" subjects_affected="35" subjects_at_risk="134"/>
                <counts group_id="E2" events="68" subjects_affected="43" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Volume overload</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Volume depletion/dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cardiovascular procedure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Non-specific chest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Non sustained VT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sustained VT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Acute MI/Cardiac Arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial flutter/fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Persistent atrial flutter/fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation/flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Electro Mechanical Dis-association</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Edema/weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cardiac Transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Coronary Artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MRSA Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Inhalant Poisoning from Cleaning Agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Change in mental status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiencies/failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dyspnea/SOB</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Worsening COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Respiratory Failure/Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sustained VT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Decompensated Heart Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Volume depletion/dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Volume overload</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Wigert</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-526-2802</phone>
      <email>dana.wigert@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

